Hua Medicine (Shanghai) Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HUMDF research report →
Companywww.huamedicine.com
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D.
- CEO
- Li Chen
- IPO
- 2021
- Employees
- 168
- HQ
- Shanghai, CN
Price Chart
Valuation
- Market Cap
- $430.90M
- P/E
- 2.78
- P/S
- 5.94
- P/B
- 3.05
- EV/EBITDA
- -17.42
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 56.85%
- Op Margin
- -29.40%
- Net Margin
- 226.82%
- ROE
- 107.22%
- ROIC
- -10.97%
Growth & Income
- Revenue
- $480.21M · 87.66%
- Net Income
- $1.08B · 530.87%
- EPS
- $1.12 · 548.00%
- Op Income
- $-141,143,190
- FCF YoY
- 85.85%
Performance & Tape
- 52W High
- $0.50
- 52W Low
- $0.15
- 50D MA
- $0.44
- 200D MA
- $0.42
- Beta
- 0.84
- Avg Volume
- 995
Get TickerSpark's AI analysis on HUMDF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our HUMDF Coverage
We haven't published any research on HUMDF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HUMDF Report →